193 related articles for article (PubMed ID: 24264380)
21. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.
Gruson D; Mancini M; Ahn SA; Rousseau MF
Clin Chim Acta; 2014 Feb; 429():189-93. PubMed ID: 24365381
[TBL] [Abstract][Full Text] [Related]
22. Renal function largely influences Galectin-3 prognostic value in heart failure.
Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
[TBL] [Abstract][Full Text] [Related]
23. Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction.
Grupper A; Nativi-Nicolau J; Maleszewski JJ; Geske JR; Kremers WK; Edwards BS; Kushwaha SS; Pereira NL
JACC Heart Fail; 2016 Nov; 4(11):847-856. PubMed ID: 27614937
[TBL] [Abstract][Full Text] [Related]
24. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Stolen CM; Adourian A; Meyer TE; Stein KM; Solomon SD
J Card Fail; 2014 Nov; 20(11):793-9. PubMed ID: 25106783
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study.
Oikonomou E; Karlis D; Tsalamadris S; Siasos G; Chrysohoou C; Vogiatzi G; Dimitropoulos S; Charalambous G; Kouskouni E; Tousoulis D
Curr Vasc Pharmacol; 2019; 17(4):396-400. PubMed ID: 29968538
[TBL] [Abstract][Full Text] [Related]
26. Correlation between mast cell density and myocardial fibrosis in congestive heart failure patients.
Batlle M; Pérez-Villa F; Lázaro A; Garcia-Pras E; Ramirez J; Ortiz J; Orús J; Roqué M; Heras M; Roig E
Transplant Proc; 2007 Sep; 39(7):2347-9. PubMed ID: 17889184
[TBL] [Abstract][Full Text] [Related]
27. Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure.
Gruson D; Mancini M; Ahn SA; Rousseau MF
Clin Biochem; 2014 Aug; 47(12):1006-9. PubMed ID: 24925289
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.
Batlle M; Pérez-Villa F; Lázaro A; García-Pras E; Vallejos I; Sionis A; Castel MA; Roig E
Transplant Proc; 2009; 41(6):2231-3. PubMed ID: 19715883
[TBL] [Abstract][Full Text] [Related]
29. Galectin-3 increase in endurance athletes.
Hättasch R; Spethmann S; de Boer RA; Ruifrok WP; Schattke S; Wagner M; Schroeckh S; Durmus T; Schimke I; Sanad W; Baumann G; Borges AC; Knebel F
Eur J Prev Cardiol; 2014 Oct; 21(10):1192-9. PubMed ID: 23723328
[TBL] [Abstract][Full Text] [Related]
30. The association among biomarkers of renal and heart function in patients with heart failure: the role of NGAL.
Oikonomou E; Tsalamandris S; Karlis D; Siasos G; Chrysohoou C; Vogiatzi G; Dimitropoulos S; Charalambous G; Kouskouni E; Tousoulis D
Biomark Med; 2018 Dec; 12(12):1323-1330. PubMed ID: 30511581
[TBL] [Abstract][Full Text] [Related]
31. Fibrosis in heart failure subtypes.
Toprak G; Yüksel H; Demirpençe Ö; Islamoglu Y; Evliyaoglu O; Mete N
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2302-9. PubMed ID: 24065222
[TBL] [Abstract][Full Text] [Related]
32. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
Gehlken C; Suthahar N; Meijers WC; de Boer RA
Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
[TBL] [Abstract][Full Text] [Related]
33. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.
Meijers WC; van der Velde AR; Ruifrok WP; Schroten NF; Dokter MM; Damman K; Assa S; Franssen CF; Gansevoort RT; van Gilst WH; Silljé HH; de Boer RA
J Am Heart Assoc; 2014 Sep; 3(5):e000962. PubMed ID: 25237044
[TBL] [Abstract][Full Text] [Related]
34. Serial galectin-3 and future cardiovascular disease in the general population.
van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
[TBL] [Abstract][Full Text] [Related]
35. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
[TBL] [Abstract][Full Text] [Related]
36. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
Leone M; Iacoviello M
Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
[TBL] [Abstract][Full Text] [Related]
37. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
Meijers WC; van der Velde AR; de Boer RA
Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support.
Schipper ME; Scheenstra MR; van Kuik J; van Wichen DF; van der Weide P; Dullens HF; Lahpor J; de Jonge N; De Weger RA
J Heart Lung Transplant; 2011 Jul; 30(7):805-10. PubMed ID: 21531579
[TBL] [Abstract][Full Text] [Related]
39. Galectin-3, a prognostic marker--and a therapeutic target?
Pereira AR; Menezes Falcão L
Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
[TBL] [Abstract][Full Text] [Related]
40. Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure.
Kaye DM; Khammy O; Mariani J; Maeder MT
Eur J Heart Fail; 2013 Mar; 15(3):292-8. PubMed ID: 23143794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
